October 4, 2012
Daiichi Sankyo announced on October 2 that it has discontinued its multinational PIII study of ARQ197 (tivantinib) for the treatment of non-small cell lung cancer (NSCLC) at the recommendation of the study’s independent Data Monitoring Committee (DMC). The company was...read more